NCT03160638View on ClinicalTrials.gov

Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

May 22, 2022

Study Completion Date

May 22, 2022

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

Azithromycin 250 mg

Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1

Trial Locations (1)

9700RB

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT03160638 - Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter